Verastem, Inc. (2VSA.F)
EUR 6.4
(0.79%)
EUR 6.4
(0.79%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 149.71 Million USD | 57.51% |
| 2022 | 95.05 Million USD | -12.53% |
| 2021 | 108.66 Million USD | -29.6% |
| 2020 | 154.34 Million USD | 6.41% |
| 2019 | 145.04 Million USD | -47.68% |
| 2018 | 277.23 Million USD | 208.76% |
| 2017 | 89.79 Million USD | 7.37% |
| 2016 | 83.62 Million USD | -26.05% |
| 2015 | 113.09 Million USD | 14.64% |
| 2014 | 98.64 Million USD | -21.25% |
| 2013 | 125.26 Million USD | 34.8% |
| 2012 | 92.92 Million USD | 57.4% |
| 2011 | 59.03 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 123.53 Million USD | -17.49% |
| 2024 Q2 | 105.74 Million USD | -14.4% |
| 2023 Q1 | 120.87 Million USD | 27.17% |
| 2023 Q3 | 176.15 Million USD | -8.14% |
| 2023 Q4 | 149.71 Million USD | -15.01% |
| 2023 Q2 | 191.75 Million USD | 58.64% |
| 2023 FY | 149.71 Million USD | 57.51% |
| 2022 Q2 | 100.4 Million USD | -13.55% |
| 2022 Q4 | 95.05 Million USD | -14.44% |
| 2022 FY | 95.05 Million USD | -12.53% |
| 2022 Q1 | 116.14 Million USD | 6.89% |
| 2022 Q3 | 111.09 Million USD | 10.64% |
| 2021 Q2 | 123.89 Million USD | -9.5% |
| 2021 FY | 108.66 Million USD | -29.6% |
| 2021 Q3 | 111.87 Million USD | -9.7% |
| 2021 Q4 | 108.66 Million USD | -2.87% |
| 2021 Q1 | 136.9 Million USD | -11.3% |
| 2020 Q2 | 198.53 Million USD | -4.62% |
| 2020 Q1 | 208.15 Million USD | 43.51% |
| 2020 Q4 | 154.34 Million USD | -29.12% |
| 2020 FY | 154.34 Million USD | 6.41% |
| 2020 Q3 | 217.77 Million USD | 9.69% |
| 2019 Q2 | 218.54 Million USD | -10.2% |
| 2019 Q1 | 243.36 Million USD | -12.22% |
| 2019 FY | 145.04 Million USD | -47.68% |
| 2019 Q4 | 145.04 Million USD | -24.69% |
| 2019 Q3 | 192.6 Million USD | -11.87% |
| 2018 Q3 | 183.15 Million USD | 5.92% |
| 2018 Q2 | 172.91 Million USD | 152.76% |
| 2018 Q1 | 68.41 Million USD | -23.81% |
| 2018 FY | 277.23 Million USD | 208.76% |
| 2018 Q4 | 277.23 Million USD | 51.37% |
| 2017 Q4 | 89.79 Million USD | 42.21% |
| 2017 Q3 | 63.13 Million USD | 2.1% |
| 2017 Q2 | 61.83 Million USD | -18.9% |
| 2017 FY | 89.79 Million USD | 7.37% |
| 2017 Q1 | 76.24 Million USD | -8.82% |
| 2016 Q2 | 95.42 Million USD | -6.96% |
| 2016 Q4 | 83.62 Million USD | -6.08% |
| 2016 FY | 83.62 Million USD | -26.05% |
| 2016 Q1 | 102.56 Million USD | -9.31% |
| 2016 Q3 | 89.04 Million USD | -6.68% |
| 2015 FY | 113.09 Million USD | 14.64% |
| 2015 Q4 | 113.09 Million USD | -8.55% |
| 2015 Q3 | 123.66 Million USD | -8.87% |
| 2015 Q2 | 135.69 Million USD | -4.44% |
| 2015 Q1 | 142 Million USD | 43.95% |
| 2014 Q3 | 97.88 Million USD | -8.81% |
| 2014 Q1 | 115.72 Million USD | -7.61% |
| 2014 FY | 98.64 Million USD | -21.25% |
| 2014 Q2 | 107.34 Million USD | -7.24% |
| 2014 Q4 | 98.64 Million USD | 0.78% |
| 2013 Q3 | 132.42 Million USD | 65.62% |
| 2013 Q1 | 86.24 Million USD | -7.19% |
| 2013 FY | 125.26 Million USD | 34.8% |
| 2013 Q4 | 125.26 Million USD | -5.41% |
| 2013 Q2 | 79.96 Million USD | -7.28% |
| 2012 Q3 | 98.83 Million USD | -6.47% |
| 2012 Q4 | 92.92 Million USD | -5.98% |
| 2012 Q2 | 105.66 Million USD | -4.55% |
| 2012 Q1 | 110.7 Million USD | 87.52% |
| 2012 FY | 92.92 Million USD | 57.4% |
| 2011 Q4 | 59.03 Million USD | -5.94% |
| 2011 FY | 59.03 Million USD | 0.0% |
| 2011 Q3 | 62.76 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| BioNTech SE | 23 Billion EUR | 99.349% |
| CureVac N.V. | 788.89 Million EUR | 81.022% |
| Biotest Aktiengesellschaft | 1.44 Billion EUR | 89.634% |
| Biotest Aktiengesellschaft | 1.44 Billion EUR | 89.634% |
| BRAIN Biotech AG | 70.93 Million EUR | -111.058% |
| Formycon AG | 890.36 Million EUR | 83.185% |
| Heidelberg Pharma AG | 70.35 Million EUR | -112.81% |
| Medigene AG | 31.71 Million EUR | -372.058% |